Risk of pregnancy-associated venous thromboembolism(VTE) in thrombophilic women without prior disease.
| Thrombophilia . | Relative Risk of VTE OR (95% CI) . | Estimated absolute risk of VTE events per 1000 patients* . |
|---|---|---|
| *Assuming a baseline risk of 1 event per 1000 pregnant patients without a known thrombophilia | ||
| Data are from Robertson et al.36 | ||
| Abbreviations: OR, Odds Ratio; CI, Confidence Interval; MTHFR, methylene tetrahydrate folate reductase | ||
| Factor V Leiden (heterozygous) | 8.32 (5.44–12.70) | 8/1000 |
| Prothrombin gene variant (heterozygous) | 6.80 (2.46–18.77) | 6/1000 |
| Factor V Leiden (homozygous) | 34.40 (9.86–120.05) | 34/1000 |
| Prothrombin gene variant (homozygous) | 26.36 (1.24–559.20) | 26/1000 |
| Antithrombin deficiency | 4.69 (1.30–16.96) | 4/1000 |
| Protein C deficiency | 4.76 (2.15–10.57) | 4/1000 |
| Protein S deficiency | 3.19 (1.48–6.88) | 3/1000 |
| MTHFR C677T (homozygous) | 0.74 (0.22–2.48) | 1/1000 |
| Thrombophilia . | Relative Risk of VTE OR (95% CI) . | Estimated absolute risk of VTE events per 1000 patients* . |
|---|---|---|
| *Assuming a baseline risk of 1 event per 1000 pregnant patients without a known thrombophilia | ||
| Data are from Robertson et al.36 | ||
| Abbreviations: OR, Odds Ratio; CI, Confidence Interval; MTHFR, methylene tetrahydrate folate reductase | ||
| Factor V Leiden (heterozygous) | 8.32 (5.44–12.70) | 8/1000 |
| Prothrombin gene variant (heterozygous) | 6.80 (2.46–18.77) | 6/1000 |
| Factor V Leiden (homozygous) | 34.40 (9.86–120.05) | 34/1000 |
| Prothrombin gene variant (homozygous) | 26.36 (1.24–559.20) | 26/1000 |
| Antithrombin deficiency | 4.69 (1.30–16.96) | 4/1000 |
| Protein C deficiency | 4.76 (2.15–10.57) | 4/1000 |
| Protein S deficiency | 3.19 (1.48–6.88) | 3/1000 |
| MTHFR C677T (homozygous) | 0.74 (0.22–2.48) | 1/1000 |